ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 117 filers reported holding ARBUTUS BIOPHARMA CORP in Q1 2022. The put-call ratio across all filers is 1.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $357,562 | -15.9% | 176,139 | -4.7% | 0.00% | – |
Q2 2023 | $425,282 | -62.4% | 184,905 | -50.5% | 0.00% | – |
Q1 2023 | $1,131,506 | +162.2% | 373,434 | +101.6% | 0.00% | – |
Q4 2022 | $431,535 | +20.9% | 185,208 | -0.8% | 0.00% | – |
Q3 2022 | $357,000 | -19.4% | 186,776 | +14.4% | 0.00% | – |
Q2 2022 | $443,000 | -9.4% | 163,307 | -0.5% | 0.00% | – |
Q1 2022 | $489,000 | – | 164,130 | +16412900.0% | 0.00% | – |
Q2 2021 | $0 | -100.0% | 1 | -99.7% | 0.00% | – |
Q1 2021 | $1,000 | -99.2% | 300 | -98.4% | 0.00% | – |
Q3 2017 | $119,000 | +72.5% | 19,200 | 0.0% | 0.00% | – |
Q2 2017 | $69,000 | +11.3% | 19,200 | 0.0% | 0.00% | – |
Q1 2017 | $62,000 | +31.9% | 19,200 | 0.0% | 0.00% | – |
Q4 2016 | $47,000 | -28.8% | 19,200 | 0.0% | 0.00% | – |
Q3 2016 | $66,000 | -1.5% | 19,200 | 0.0% | 0.00% | – |
Q2 2016 | $67,000 | -15.2% | 19,200 | 0.0% | 0.00% | – |
Q1 2016 | $79,000 | -7.1% | 19,200 | 0.0% | 0.00% | – |
Q4 2015 | $85,000 | +19.7% | 19,200 | +65.5% | 0.00% | – |
Q3 2015 | $71,000 | – | 11,600 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JACOB ASSET MANAGEMENT OF NEW YORK LLC | 340,000 | $1,459,000 | 0.53% |
RTW INVESTMENTS, LP | 4,733,323 | $20,306,000 | 0.31% |
APIS CAPITAL ADVISORS, LLC | 70,000 | $300,000 | 0.29% |
Hudson Bay Capital Management LP | 1,800,000 | $7,722,000 | 0.10% |
COWEN AND COMPANY, LLC | 249,215 | $1,069,000 | 0.05% |
Kerrisdale Advisers, LLC | 100,000 | $429,000 | 0.05% |
Woodline Partners LP | 496,172 | $2,129,000 | 0.04% |
Shay Capital LLC | 60,000 | $257,000 | 0.03% |
Walleye Capital LLC | 231,037 | $991,000 | 0.03% |
BOOTHBAY FUND MANAGEMENT, LLC | 212,700 | $912,000 | 0.02% |